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Organ motionPurpose: A study of real-time adaptive radiotherapy systems was performed to test the hypothesis that,
across delivery systems and institutions, the dosimetric accuracy is improved with adaptive treatments
over non-adaptive radiotherapy in the presence of patient-measured tumor motion.
Methods and materials: Ten institutions with robotic(2), gimbaled(2), MLC(4) or couch tracking(2) used
common materials including CT and structure sets, motion traces and planning protocols to create a lung
and a prostate plan. For each motion trace, the plan was delivered twice to a moving dosimeter; with and
without real-time adaptation. Each measurement was compared to a static measurement and the per-
centage of failed points for c-tests recorded.
Results: For all lung traces all measurement sets show improved dose accuracy with a mean 2%/2 mm c-
fail rate of 1.6% with adaptation and 15.2% without adaptation (p < 0.001). For all prostate the mean
2%/2 mm c-fail rate was 1.4% with adaptation and 17.3% without adaptation (p < 0.001). The difference
between the four systems was small with an average 2%/2 mm c-fail rate of <3% for all systems with
adaptation for lung and prostate.
Conclusions: The investigated systems all accounted for realistic tumor motion accurately and performed
to a similar high standard, with real-time adaptation significantly outperforming non-adaptive delivery
methods.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 159–165
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Real-time adaptive radiotherapy has been developed to account
for intrafraction motion during radiotherapy treatment delivery. It
allows certainty in the dose delivery and for increased dose to the
target through the implementation of stereotactic body radiother-
apy (SBRT).There are three ways to account for patient motion in real-time
adaptive radiotherapy; shifting the treatment source, shifting the
beam or adjusting the patient position. The first commercial real-
izations of real-time adaptive radiotherapy were the CyberKnife
Synchrony robotic tracking system (Accuray, Incorporated, Sunny-
vale, CA) in 2004 [1] and the MHI Vero tracking gimbaled linac sys-
tem (Mitsubishi Heavy Industries, Ltd., Japan and BrainLAB AG,
Feldkirchen, Germany) in 2011 [2]. Both systems are new machine
designs that shift the treatment source to track the motion of the
160 Multi-institute real-time adaptive studytumors. Multi-leaf collimator (MLC) tracking is a real-time adapta-
tion technique implemented on a conventional linac that shifts the
treatment beam to follow the tumor motion. The first clinical
implementation of MLC tracking was done for prostate cancer
treatment in 2013 [3]. Couch tracking is another system undergo-
ing research, development and clinical translation and relies on
shifting of the patient and tumor relative to the stationary treat-
ment beam [4,5].
Until now, the geometric and dosimetric assessments of real-
time adaptive radiotherapy systems have been performed inde-
pendently with extensive pre-clinical and clinical research done
into robotic tracking [6,7], gimbaled tracking [8–10], MLC tracking
[11–13] and couch tracking [4,5,14]. The aim of this study was to
assess the dosimetric accuracy of real-time adaptive treatments
over non-adaptive radiotherapy in the presence of patient-
derived tumor motion using a common set of tools.
Methods and materials
Common materials
The philosophy of the study was to keep as much of the equip-
ment and technique in common as possible, such as patient CT
images, structures (e.g. target and organ-at-risk contours and
CTV-PTVmargins), planning dosimetric constraints, patient motion
files and analysis metrics. An overview of the study is presented in
Fig. 1.
Contours
The lung contours were obtained from a stage I non-small cell
lung cancer patient. The tumor volume was 7.2 cm3, which was
the median size tumor of the 21 patients in the series [15]. The
contour definitions and margins were per Radiation Therapy
Oncology Group (RTOG) 1021. The CTV (=GTV) to PTV margins
were 5 mm in all directions. This margin deviated from the RTOG
guidelines of 5 mm laterally and 10 mm in the superior–inferior
direction as the tumor motion is explicitly accounted for. For sim-
ilarity across all platforms, only a single phase (end-exhale) of the
4DCT scan was used, simulating a single phase or breath hold scan
for clinical use. The use of a single phase did not account for target
or normal tissue deformation, however for the case chosen there
was minimal deformation of the target from phase to phase.
The prostate contours were acquired from a patient with an
average prostate volume (55.3 cm3) as determined from a previous
study [16]. The contour definitions were per RTOG 0938. Note that
0938 explicitly included and stratified for both robotic tracking and
linac-based treatments. The CTV to PTV margins were 3 mm poste-
riorly and 5 mm elsewhere. All data sets were anonymized for this
study.
Dose prescription
The lung stereotactic dose was 54 Gy in 3 fractions, prescribed
to 95% of the PTV volume (PTV D95) as per RTOG 1021. The dose
constraints used were from the SBRT arm of RTOG 1021.
The prostate stereotactic dose prescription was 36.25 Gy in 5
fractions, prescribed to the PTV D95 as per RTOG 0938. The dose
constraints used were from the five-fraction arm of RTOG 0938.
Motion traces
Four lung tumor and four prostate tumor motion traces were
selected from large databases of patients measured with the
CyberKnife Synchrony [17] (25 Hz sampling frequency) and the
Calypso [18] (Varian Medical Systems, Palo Alto, CA, USA) (10 Hz
sampling frequency) systems, respectively (Fig. 2). The traces were
selected because they represented a variety of observed categories
of motion for lung and prostate tumors. For lung a typical lungmotion trace was selected representative of the majority of lung
motion during treatments with the motion predominantly in the
superior–inferior direction, three other more atypical traces were
selected including motion predominantly in the left–right direc-
tion, high frequency motion and a trace with baseline shifts. A
stable trace was selected for the prostate which represents the
majority of prostate motions and three atypical motion traces were
also selected including continuous drift, high frequency and erratic
traces. Additionally, for the lung a one-dimensional (superior–infe-
rior) sinusoidal motion trace was included with 1.5 cm range and
4 s period. The lung tumor traces also had an observed external
surrogate motion for use by systems that rely on combined inter-
nal and external motion monitoring. When three degrees of free-
dom were not available to use for motion correction, the
superior–inferior motion trace was used and the same external
surrogate motion used. Each trace was 400 s in length, and it was
repeated from the beginning, until the end of the delivery if the
delivery was longer than 400 s.Institution specific materials and methods
Overall 10 institutions with real-time adaptive radiotherapy
systems participated in the study; two robotic tracking, two gim-
baled tracking, four MLC tracking and two couch tracking institu-
tions. The different institutions had different planning systems,
dosimetry phantoms and motion platforms. The preferred dosime-
try equipment was a volumetric-type detector and a motion plat-
form to allow programable motion in at least one dimension
(Table 1). For consistency, all treatments were performed with
6MV treatment beams.
The systems used by the ten institutions are shown in Table 1.
The two robotic tracking institutions both used a CyberKnife
Robotic Radiosurgery System and the multiplan planning system
version 3.5 and 4.6 and the Synchrony system, kV and optical
imaging was used as the motion guidance system. The institutions
using gimbaled tracking both implemented the technique using
the Vero system and iPlan 4.5.3 planning system (BrainLAB AG,
Feldkirchen, Germany). kV only and combined kV and optical
imaging was for motion guidance. MLC tracking was performed
at four institutions; using a Varian Trilogy linac with Millennium
MLC, a Varian Truebeam linac with millennium MLC, an Varian
Novalis Tx linac with HD MLC (Varian Medical Systems, Palo Alto,
CA) and an Elekta Synergy linac with Agility MLC (Elekta AB, Stock-
holm, Sweden). All used Eclipse planning system (Varian Medical
Systems, Palo Alto, CA, USA) except for the last which used Pinna-
cle 9.8 (Philips Radiation Oncology Systems, Milpitas, CA). The two
institutions implementing MLC tracking on the Varian platform
used a Calypso input signal. The MLC tracking implemented on
the Novalis used ExacTrac optical tracking (BrainLAB AG, Feld-
kirchen, Germany) and on the Synergy a motion signal from the
motion platform was used with additional latency and noise
(100 ± 10 ms). Couch tracking was implemented on a Varian tril-
ogy linac using a Protura couch (Civco Medical Solutions) and
Eclipse planning system and an Elekta Synergy using a HexaPOD
evo RT system couch (Elekta AB, Stockholm, Sweden) and Pinnacle
planning system. Both institutions used optical tracking for motion
guidance.
All motion platforms used in this study had sub-millimeter
accuracy with eight of the ten institutions using 3D or 4D (3D tar-
get motion plus external surrogate) motion for the lung measure-
ments and two institutions using 1D programable motion
platforms for lung measurements.
Five of the institutions used the Delta4 detector (ScandiDos AB,
Uppsala, Sweden) which is comprised of two crossed panel diode
arrays and has a spatial resolution of 5 mm centrally and 10 mm
on the periphery. One institution used the arcCHECK (Sun Nuclear
Fig. 1. Overview of the materials and methods of the study.
E. Colvill et al. / Radiotherapy and Oncology 119 (2016) 159–165 161Corp., Melbourne, FL) dosimeter which is a cylindrical diode array
with a detector spacing of 10 mm. One institution used the Octa-
vius (PTW, Freiburg) which uses 2D ion chamber array with detec-
tor spacing of 2.5 mm. The other three institutions used film
phantoms including a stereotactic Dose Verification Phantom
(Standard Imaging Inc., Middleton, WI, USA), the I’mRT phantom
(IBA, Schwarzenbruck, German) and the Quasar Respiratory Phan-
tom (Modus Medical, Ontario, Canada) with Gafchromic EBT3film
(ISP, Wayne, NJ) with a positional accuracy of 0.5 mm and absolutedosimetric accuracy of 1.5% based the recommended analysis pro-
tocol for Gafchromic EBT3.Data collected
All participating institutions used standardized forms to report
results. Data reported for the lung plan were the PTV homogeneity
index (HI) ½HI ¼ ðD2D98ÞD50 , PTV conformity index (CI) (CI = the vol-
ume receiving the prescription isodose divided by the volume of
Fig. 2. Patient-measured (a) lung and (b) prostate tumor motion traces used for this study. The fifth lung trace (not pictured) is a 1D (superior–inferior) sinusoidal motion
trace with range 1.5 cm and 4 s period.
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PTV CI, mean rectal dose, and mean bladder dose were reported.
The dosimetric results reported by each institution were the per-
centage of points passing 3%/3 mm, 2%/2 mm and 1%/1 mm global
c-tests (normalized to the maximum dose of the static reference
and using 10% low dose cutoff) for motion with and without
real-time adaptation for all four prostate motion traces and five
lung traces. Institutions using film measurements used a 20% low
dose cut off rather than 10% for the c analysis due to a restriction
in film size. Treatment delivery time was also reported by the
institutions.
All institutions reported planning and dosimetric results for
lung and nine of the ten institutions reported planning and dosi-
metric prostate results. As clinical prostate treatments have not
been performed using real-time adaptation on the gimbaled track-
ing system to date, one institution did not report prostate planning
and dosimetric results. The remaining gimbaled tracking institu-
tion reported 3%/3 mm c-tests only, due to measurement device
accuracy.Statistical analysis
The Wilcoxon signed-ranked test was used to test the hypothe-
sis, that real-time adaptive radiotherapy improves the dosimetric
accuracy over non-adaptive radiotherapy in the presence of realis-
tic tumor motion, between the sets of motion traces and between
each adaptation type and the total collective adaptation and no
motion adaptation sets. A p-value of less than 0.05 was considered
to be statistically significant.Results
The planning results showing the mean and range of CI, HI and
mean organ at risk doses (mean lung, rectal and bladder doses),
along with the treatment delivery times are shown in Table 2.
When comparing real-time adaptation to without adaptation
for all ten institution sets combined there was a significant differ-
ence (p < 0.001) for both lung and prostate, for 3%/3 mm, 2%/2 mm,
and 1%/1 mm c-fail rates. For all lung traces (combined) all institu-
tion measurement sets showed improved dose accuracy with a
mean 2%/2 mm c-fail rate of 1.6% with adaptation and 15.2% with-
out adaptation (p < 0.001). All prostate traces (combined) also had
improved accuracy, the mean 2%/2 mm c-fail rate was 1.4% with
adaptation and 17.3% without adaptation (p < 0.001). The mean
(±1 SD) percentage of points that failed the 3%/3 mm, 2%/2 mm
and 1%/1 mm c-tests for each trajectory with all institution sets
combined and the c-fail rates for each real-time adaptation system
when all motion trajectory results were combined are available in
the Supplemental material.
For both lung and prostate the high frequency motion traces
resulted in the highest c-fail rates while both the typical lung
and the stable prostate traces resulted in the lowest c-fail rates.
The mean of the institution c-fail rates for the 3%/3 mm c criteria
without adaptation was 19.0% and 8.5% for the high frequency lung
and prostate traces respectively. These c-fail rates were reduced
with adaptation to 0.1% for both lung and prostate. Similarly for
the 2%/2 mm and 1%/1 mm c-tests the high frequency for both
lung and prostate had the highest c-fail rates without adaptation
and with adaptation these c-fail rates were significantly reduced
(p < 0.001).
All four real-time adaptation systems performed similarly for
both lung and prostate using the 3%/3 mm and 2%/2 mm test c cri-
teria. Larger differences were seen in the results of the 1%/1 mm c-
tests particularly for lung where the gimbaled tracking with adap-
tation did not result in a significant change from without adapta-
Table 2
Mean and range of the reported planning values and average delivery time for the lung and prostate plans for all ten institutions measurement sets.
Adaptation type
Robotic tracking Gimbaled tracking MLC tracking Couch tracking
Lung
CI 1.15 (1.11–1.19) 1.15 (1.11–1.2) 0.99 (0.95–1.09) 0.98 (0.97–0.98)
HI 0.41 (0.39–0.42) 0.58 (0.5–0.65) 0.31 (0.17–0.51) 0.41 (0.38–0.43)
Mean lung dose (Gy) 3.9 (3.7–4.2) 2.8 (2.7–2.99) 2.9 (2.6–3.2) 2.9 (2.6–3.2)
Treatment time (min) 36.5 (30–43) 18 (16–19.5) 8.2 (6.2–11) 11.5 (8–15)
Prostate
CI 1.13 (1.05–1.21) 1.1 1.07 (0.97–1.16) 1.02 (0.99–1.04)
HI 0.17 (0.16–0.17) 0.04 0.05 (0.03–0.06) 0.04 (0.02–0.05)
Mean rectal dose (Gy) 14.3 (12.0–16.7) 13.3 12.6 (7.89–16.93) 9.2 (8.4-10)
Mean bladder dose (Gy) 12.8 (11.4–14.3) 7.5 7.3 (5.9–8.9) 7.0 (6.5–7.5)
Treatment time (min) 37 (30–43.5) 10 4.5 (3–6) 4 (3–4.5)
CI = Conformity index.
HI = Homogeneity index.
164 Multi-institute real-time adaptive studytion. MLC tracking had four sets of measurements while the other
adaptation systems had at most two sets, only one gimbaled track-
ing set for prostate was reported.
Discussion
Across four delivery systems and for a range of prostate and
lung motions we have shown that real-time adaptation offers
superior dose conformality to current delivery techniques. Small
differences in the dosimetric fidelity of the four real-time adapta-
tion systems in this study were observed for 3%/3 mm c-tests. A
larger dosimetric difference was observed between using real-
time adaptive radiotherapy and no adaptation, the most common
current treatment. It is worth noting that when the dosimetric dif-
ferences between real-time adaptation and no adaptation are put
in the context of other dosimetric errors in radiotherapy, we can
conclude that motion is a leading order dosimetric error. The addi-
tion of motion (without adaptation) results in mean 3%/3 mm c-
fail rates much higher than the 2.1% mean fail rates seen for con-
ventional IMRT commissioning where no motion is considered
[19]. Random errors were not modeled for the conventional arm
of study, but are implicitly accounted for within the adaptive
arm. These results indicate that independent of the method used
to account for motion in real-time, substantial treatment quality
gains can be made by implementing real-time adaptive
radiotherapy.
All four real-time adaptation systems were comparable when
assessed by 3%/3 mm and 2%/2 mm c-tests. The main difference
was seen with the stricter 1%/1 mm criterion and is likely due to
planning and measurement rather than a difference in dose deliv-
ery as many different treatment planning systems, motion plat-
forms and detectors were used. In particular, the gimbaled
tracking 1%/1 mm c-test results in this study (measured using film
dosimetry) do not mirror the results of previous geometric accu-
racy studies [9,20] that demonstrate high geometric accuracy com-
parable with other real-time adaptation techniques. The outcome
of the statistical analysis may have been affected by the sample
size as MLC tracking had four sets of measurements while the
other adaptation systems had at most two sets, only one gimbaled
tracking set for prostate was reported.
The dosimetric failures were observed to be both inside the high
dose target volumes and in the low dose areas toward the edges of
the dose distributions for both the lung and prostate cases, with
lung results showing a greater number of failures near the edge
of the target volumes potentially because of the larger motion tra-
jectories and steeper dose gradients. The cause of the failures is a
complex interaction between the plan complexity, delivery timewith respect to motion, dose delivery angle and position with
respect to motion and various real-time adaptation technique
specific factors.
Planning using different treatment planning systems for differ-
ent treatment techniques and platforms means that there are dif-
ferences in the treatment plans used by the institutions in this
study. These differences in plans, such as the steepness of dose gra-
dients, could have an effect on the c-test results. The ranges of both
the CI and HI (Table 2) of the plans for the different real-time adap-
tation systems have overlapped in this study but are not exactly
the same and this will have carried through to the dosimetric
results.
The delivery systems have some key differences including
motion detection, prediction and correction strategies, however
the overall results are similar in that they effectively account for
intrafraction motion during dose delivery as evident in the
3%/3 mm results in this study.
A notable difference in the results is the delivery times, with
robotic tracking taking the longest time to deliver a plan and both
robotic tracking and gimbaled tracking having significantly longer
treatment times than those of the MLC tracking and couch tracking
deliveries. The different planning and delivery techniques used by
each of the institutions also contribute to a range of treatment
times for all four real-time adaptation techniques.
The difference in measurement devices likely had a large effect
on the dose result comparison between the institutions in this
study. Dosimeters used in this study included diode devices Delta4
(five institutions) and ArcCHECK (one institution), the Octavius ion
chamber detector (one institution) and film dosimetry devices
(four institutions). Each of the dosimeters has different limitations
and advantages including different spatial and dosimetric accura-
cies. Future studies could use consistent dosimetry equipment
however trade-offs would still need to be made, for example the
dosimetric accuracy of ion chambers or diodes vs. the spatial reso-
lution of film.
In this study a 5 mm CTV to PTV margin was used for our lung
contour rather than the RTOG 1021 protocol of 5 mm with a 1 cm
margin in the superior–inferior direction or the use of an Internal
Target Volume (ITV) because the motion was explicitly accounted
for. Treatment margins are comprised of various components
including contouring uncertainties and tumor deformation as well
as potential motion related factors of specific real-time adaptation
techniques such as surrogacy uncertainties and residual motion
due to tracking and delivery accuracy. The results presented here
in the form of gamma failure rates cannot directly be translated
into margin reductions but could allow for increased confidence
in the delivery of existing plans.
E. Colvill et al. / Radiotherapy and Oncology 119 (2016) 159–165 165Real-time adaptive technologies will evolve and improve fur-
ther in their geometric and dosimetric fidelity as localization
methods improve, latency times are reduced, prediction algo-
rithms improve, and hardware limitations, such as velocity and
acceleration constraints, are overcome. The results presented here
can be considered as a snapshot in time and can be used as a
benchmark for future system improvements or for yet-to-be-
developed real-time adaptive radiotherapy systems. The real-
time adaptive results will continue to get closer to results that
would be achieved if no motion were present; the no motion com-
pensation results will stay the same. Therefore the dosimetric dif-
ference between real-time adaptive radiotherapy and no motion
compensation will continue to increase.
Conclusion
A multi-institutional comparison study encompassing robotic,
gimbaled, multileaf collimator and couch tracking was performed
between real-time adaptive radiotherapy systems and non-
adaptive radiotherapy. The results show that the systems all
account for realistic tumor motion accurately and performed to a
similar high standard, with real-time adaptation significantly out-
performing non-adaptive methods. To enable the performance of
this study at any radiotherapy center, the input data, method
and report forms can be downloaded from http://sydney.edu.au/
medicine/radiation-physics/data/real-time-benchmarking-data.
php
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